Jordyn Sava is an editor for Targeted Oncology.
Behind the FDA Approval of Liso-cel for Relapsed/Refractory CLL/SLL
March 15th 2024In an interview with Targeted Oncology, Tanya Siddiqi, MD, discussed the rationale behind the TRANSCEND CLL 004 study supporting the FDA approval of lisocabtagene maraleucel in chronic lymphocytic leukemia or small lymphocytic lymphoma.
FDA Approves Liso-Cel in Relapsed or Refractory CLL/SLL
March 15th 2024The current indication of lisocabtagene maraleucel has been expanded to include adult patients with relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma who received a prior BTK inhibitor and B-cell lymphoma 2 inhibitor.
Optimizing Thyroid Cancer Care: New Tools and Emerging Options
March 12th 2024Lori J. Wirth, MD, discussed advancements in diagnosing and treating thyroid cancer, offering community oncologists improved tools for identifying low-risk cancers, personalizing treatment, and exploring innovative approaches.
Unraveling Communication Challenges in MDS Treatment
March 4th 2024In an interview with Targeted Oncology, Claire Saxton, MBA, and Ashley Moncrief, discussed the importance of education efforts focused on ensuring that patients with MDS understand their diagnosis and options so that they can make informed decisions about their care.
Enhancing Precision in Immunotherapy: CD8 PET-Avidity in RCC
March 1st 2024In this episode of Emerging Experts, Peter Zang, MD, highlights research on baseline CD8 lymph node avidity with 89-Zr-crefmirlimab for the treatment of patients with metastatic renal cell carcinoma and response to immunotherapy.